US pharmaceutical firm Pfizer claims that its Covid-19 tablet appears to be effective against the Omicron type. The company said it had tested the bullet on 2,250 people. The full results of this study confirm the promising preliminary results of the pill against the virus. If this drug is taken immediately after the initial symptoms of Cocovid-19, the mortality of high-risk adults can be reduced by about 89%.
The company announced that a separate laboratory test would show that the drug retains its strength against the omecron type of chronovirus. Pfizer has tested this antiviral drug against a version of a man-made protein. This new development comes at a time when the number of Cowid-19 cases, deaths and hospital admissions is on the rise again. Is increasing. In this situation, the health authorities are preparing to deal with the effects of the new Omicron type.
It is expected that the US Food and Drug Administration (FDA) will soon make a decision on allowing the use of Pfizer pills and a competitive pill made from Merck. Several weeks ago, the two pharmaceutical companies applied to the US regulator for approval of the drug. If the pills are approved, it will be the first treatment for Covid-19 that American citizens can buy at a pharmacy and take home.
Experimental statistics from Pfizer’s drug could help reassure regulators, while Merck revealed in a final test that its drug had fewer benefits than expected. Late last month, Merck said its pill was more risky Adult hospital admissions and deaths have been reduced by 30%. Both companies initially tested their drugs on adults who had not been vaccinated. They were older or had health problems such as asthma or obesity and could be at serious risk of Covid-19.
Pfizer is also testing its pill in low-risk adults. In the preliminary results, Pfizer says its medication has failed to meet its main study goal, and that was to prescribe medication for four days during or after treatment. Permanent relief from 19 but this drug has achieved the second goal by reducing the number of hospital admissions in this group by about 70%. Problems included vaccinated adults. Less than one percent of patients receiving the drug were hospitalized, while 2.4 percent were given a dummy pill.
An independent board of medical experts has analyzed the data and recommended that Pfizer continue its study to obtain complete results before approval from the US regulator. The level of the virus has decreased 10 times compared to
Pills made by both Merck and Pfizer are expected to do well against omecron because they do not target the spike protein of the coronavirus, which contains most of the new variants. The U.S. government, meanwhile, has agreed to buy enough Pfizer for the treatment of 10 million people and has agreed to buy Merck for the treatment of 3 million people. However, it is awaiting FDA approval. Is.
Asia Times Now Instagram: Click Here
Asia Times Now Facebook: Click Here
Asia Times Now Twitter: Click Here
Asia Times Now Mockrack: Click Here